1. |
Atmaca LS, Simsek T, Batioglu F. Clinical features and prognosis in ocular toxoplasmosis[J]. Jpn J Ophthalmol, 2004, 48(4): 386-391.DOI: 10.1007/s10384-003-0069-0.
|
2. |
Holland GN. Ocular toxoplasmosis: new directions for clinical investigation[J]. Ocul Immunol Inflamm, 2000, 8(1): 1-7.
|
3. |
Park YH, Han JH, Nam HW. Clinical features of ocular toxoplasmosis in Korean patients[J]. Korean J Parasitol, 2011, 49(2): 167-171.DOI: 10.3347/kjp.2011.49.2.167.
|
4. |
London NJ, Hovakimyan A, Cubillan LD, et al. Prevalence, clinical characteristics, and causes of vision loss in patients with ocular toxoplasmosis[J]. Eur J Ophthalmol, 2011, 21(6): 811-819.DOI: 10.5301/EJO.2011.6403.
|
5. |
Barb SM, Patel AV, Young LH. Toxoplasmic retinitis: to treat or not to treat and with what drug? Int Ophthalmol Clin, 2015, 55(4): 37-45. DOI: 10.1097/IIO.0000000000000088.
|
6. |
Butler NJ, Furtado JM, Winthrop KL, et al. Ocular toxoplasmosis Ⅱ: clinical features, pathology and management[J]. Clin Exp Ophthalmol, 2013, 41(1): 95-108.DOI: 10.1111/j.1442-9071.2012.02838.x.
|